With a new year in full swing, HDA President and CEO John M. Gray looked ahead to the organization’s 2019 priorities (along with other industry association executives) as part of the Chain Drug Review “Pharmacy Outlook” feature.

Last year, FDA announced a period of “enforcement discretion” related to the deadline for manufacturers to serialize products under the Drug Supply Chain Security Act (DSCSA). As the industry quickly approaches the November 2018 deadline, it is essential for companies to prepare now for the reality of conducting business in a serialized environment. Is your company ready to meet the new requirements?

Ahead of the HDA Business and Leadership Conference, President and CEO John M. Gray was interviewed by Chain Drug Review as part of the publication’s "Annual Report of Drug Wholesalers."

HDA President and CEO John M. Gray has outlined the organization’s priorities for the upcoming year in his annual “Pharmacy Outlook” column, published in the January 2 issue of Chain Drug Review.